References
- Sheridan PH, Jacobs MP. The development of antiepileptic drugs for children. Report from the NIH workshop, Bethesda, Maryland. Epilepsy Res. 1994 February;23(1):87–92. 17-18, ; doi:https://doi.org/10.1016/0920-1211(95)00043-7.
- FDA 2019. Drugs for treatment of partial onset seizures: full extrapolation of efficacy from adults to pediatric patients 2 years of age and olderGuidance for Industry. https://www.fda.gov/media/130449/download
- Rose K, Neubauer D, Grant-Kels JM. Ethical issues in pediatric regulatory studies involving placebo treatment. J Pediatr Epilepsy. 2020;9(3):073–079. https://doi.org/10.1055/s-0040-1712147
- Sun H, Temeck JW, Chambers W, et al. Extrapolation of efficacy in pediatric drug development and evidence-based medicine: progress and lessons learned. Ther Innov Regul Sci. 2017;2017:1–7.
- Kuhn TS. The structure of scientific revolutions. Second. Enlarged. international encyclopedia of unified science. Chicago IL: The University of Chicago Press. 1970;66. https://www.lri.fr/~mbl/Stanford/CS477/papers/Kuhn-SSR-2ndEd.pdf
- Rose K, Tanjinatus O, Grant-Kels JM, et al. Minors and a dawning paradigm shift in “pediatric” drug development. J Clin Pharmacol. 2020, Dec 23 https://accp1.onlinelibrary.wiley.com/doi/epdf/10.1002/jcph.1806
- Rose K. Considering the patient in pediatric drug development. how good intentions turned into harm. London: Elsevier; 2021. Available from: https://www.elsevier.com/books/considering-the-patient-in-pediatric-drug-development/rose/978-0-12-823888-2.
- Hertz S 2016. Analgesic developments for pediatric patients. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM495096.pdf
- Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012 Feb;129(2):354–364. DOI:https://doi.org/10.1542/peds.2010-3591.
- FDA 2014. Copaxone approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/020622Orig1s089ltr.pdf
- FDA 2012. Teriflunamide approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202992Orig1s000ltr.pdf
- FDA 2010. Fingolimod approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000ltr.pdf
- FDA 2013. Tecfidera approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204063Orig1s000Approv.pdf
- FDA 2020. Ozanimod (zeposia) approval package including approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/209899Orig1s000Approv.pdf
- FDA 2019. Siponimod (mayzent) approval package, including the approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000Approv.pdf
- Waubant E, Banwell B, Wassmer E, et al. Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG. Neurology. 2019 May 1;92:e2538–e2549. https://doi.org/10.1212/WNL.0000000000007572.
- Auvin S, French J, Dlugos D, et al. Novel study design to assess the efficacy and tolerability of antiseizure medications for focal-onset seizures in infants and young children: a consensus document from the regulatory task force and the pediatric commission of the International League against Epilepsy (ILAE), in collaboration with the Pediatric Epilepsy Research Consortium (PERC). Epilepsia Open. 2019 Sep 4;44:537–543. https://doi.org/10.1002/epi4.12356. eCollection 2019 Dec.FormularbeginnFormularendeFormularbeginn.
- Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019 Apr 16;9216:e1912–e1925. https://doi.org/10.1212/WNL.0000000000007316.
- Figueiredo M. FDA grants rare pediatric disease designation to trofinetide for rett syndrome. Rett Syndrome News. March 6, 2020; https://rettsyndromenews.com/2020/03/06/fda-grants-rare-pediatric-disease-designation-to-trofinetide-for-rett-syndrome/
- FDA. The pediatric exclusivity provision. January 2001. Status Report to Congress. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049915.pdf
- Hirschfeld S, Saint-Raymond A. Pediatric regulatory initiatives. Handb Exp Pharmacol. 2011;205:245–268.
- Rose K, Neubauer D, Grant-Kels JM. Rational use of medicine in children – the conflict of interests story. A Rev Rambam Maimonides Med J. 2019 Jul 18;13:e0018. Review https://doi.org/10.5041/RMMJ.10371.
- Wharton, et al. Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy. Pediatrics. 2014;134(2):e512–e518. DOI:https://doi.org/10.1542/peds.2013-2987.
- Ward RM, DK B Jr, Davis JM, et al. The need for pediatric drug development. J Pediatr. 2018 Jan;192:13–21.
- Pellock JM, Carman WJ, Thyagarajan V, et al. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012 Oct 2;7914:1482–1489. https://doi.org/10.1212/WNL.0b013e31826d5ec0.
- Pellock JM, Arzimanoglu A, D’Cruz O, et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children ≥2 years of age with focal seizures: the case for disease similarity. Epilepsia. 2017 Oct;58(10):1686–1696. DOI:https://doi.org/10.1111/epi.13859.
- Arzimanoglou A, D’Cruz O, Nordli D, et al. A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs. 2018 Jun;20(3):249–264. DOI:https://doi.org/10.1007/s40272-018-0286-0.
- Wadsworth I, Jaki T, Sills GJ, et al. Clinical drug development in epilepsy revisited: a proposal for a new paradigm streamlined using extrapolation. CNS Drugs. 2016 Nov;30(11): 1011–1017. https://doi.org/10.1007/s40263-016-0383-y.
- Chitnis T. Paediatric MS is the same disease as adult MS: no. Mult Scler. 2013 Sep;19(10):1255–1256.
- Kearns GL, Abdel-Rahman SM, Alander SW, et al. evelopmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157–1167. https://doi.org/10.1056/NEJMra035092
- Beunen GP, Rogol AD, Malina RM. Indicators of biological maturation and secular changes in biological maturation. Food Nutr Bull. 2006 Dec;27(4 Suppl Growth Standard):S244–56. DOI:https://doi.org/10.1177/15648265060274S508.
- Shirkey H. Therapeutic Orphans. J Pediatr. 1968 Jan;72(1):119–120. DOI:https://doi.org/10.1016/S0022-3476(68)80414-7.
- FDA 2016. Best pharmaceuticals for children act and pediatric research equity act. Status Report to Congress. www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM509815.pdf
- EMA 2015: EMA/PDCO summary report on the review of the list of granted class waivers. https://www.ema.europa.eu/en/documents/other/european-medicines-agency-decision-cw-0001-2015-23-july-2015-class-waivers-accordance-regulation-ec_en.pdf
- EMA 2020. Brivaracetam PIP EMEA-000332-PIP01-08-M15 https://www.ema.europa.eu/en/documents/pip-decision/p/0324/2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2021. Brivaracetam PIP EMEA-000332-PIP02-17-M01 https://www.ema.europa.eu/en/documents/pip-decision/p/0203/2020-ema-decision-12-june-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2009. Carisbamate PIP EMEA-000360-PIP01-08 https://www.ema.europa.eu/en/documents/pip-decision/p/108/2009-european-medicines-agency-decision-9-june-2009-agreement-paediatric-investigation-plan-granting_en.pdf
- EMA 2019. Eslicarbazepine PIP EMEA-000696-PIP02-10-M06 https://www.ema.europa.eu/en/documents/pip-decision/p/0272/2019-ema-decision-14-august-2019-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2015. Ethosuximide PIP EMEA-001617-PIP01-14. https://www.ema.europa.eu/en/documents/pip-decision/p/0315/2015-ema-decision-21-december-2015-agreement-paediatric-investigation-plan-granting-waiver_en.pdf
- EMA 2018. Fenfluramine PIP EMEA-001990-PIP01-16-M02 https://www.ema.europa.eu/en/documents/pip-decision/p/0354/2018-ema-decision-30-december-2018-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2020. Lacosamide PIP EMEA-000402-PIP03-17-M04 https://www.ema.europa.eu/en/documents/pip-decision/p/0330/2020-ema-decision-21-august-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA Perampanel PIP EMEA-000467-PIP01-08-M14 https://www.ema.europa.eu/en/documents/pip-decision/p/0296/2020-ema-decision-12-august-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2016. Rufinamide PIP EMEA-000709-PIP01-09-M05 https://www.ema.europa.eu/en/documents/pip-decision/p/0116/2016-ema-decision-22-april-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2017. Vigabatrin PIP EMEA-000717-PIP02-13-M02 https://www.ema.europa.eu/en/documents/pip-decision/p/0083/2017-ema-decision-17-march-2017-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2016. Retigabine PIP EMEA-000116-PIP01-07-M08 https://www.ema.europa.eu/en/documents/pip-decision/p/0009/2016-ema-decision-29-january-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2020. Alemtuzumab PIP EMEA-001072-PIP01-10-M04 https://www.ema.europa.eu/en/documents/pip-decision/p/0269/2020-ema-decision-17-july-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2010. Tabalumab PIP EMEA-000802-PIP01-09. https://www.ema.europa.eu/en/documents/pip-decision/p/252/2010-ema-decision-26-november-2010-agreement-paediatric-investigation-plan-granting-deferral_en.pdf
- EMA 2020. Daclizumab PIP EMEA-001349-PIP01-12-M03 https://www.ema.europa.eu/en/documents/pip-decision/p/0005/2020-ema-decision-6-january-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2020. Dimethyl Fumarate PIP EMEA-000832-PIP01-10-M05 https://www.ema.europa.eu/en/documents/pip-decision/p/0177/2020-ema-decision-15-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-dimethyl_en.pdf
- EMA 2017 Fingolimod PIP EMEA-000087-PIP01-07-M05 https://www.ema.europa.eu/en/documents/pip-decision/p/0050/2017-ema-decision-3-april-2017-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2014. Laquinimod PIP EMEA-000972-PIP01-10-M04 https://www.ema.europa.eu/en/documents/pip-decision/p/0086/2014-ema-decision-4-april-2014-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA Natalizumab PIP EMEA-001095-PIP02-12 https://www.ema.europa.eu/en/documents/pip-decision/p/0252/2012-ema-decision-19-october-2012-agreement-paediatric-investigation-plan-granting-deferral-granting_en.pdf
- EMA 2019. Ocrelizumab PIP EMEA-000310-PIP03-10-M03 https://www.ema.europa.eu/en/documents/pip-decision/p/0028/2019-ema-decision-29-january-2019-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2020. Ozanimod PIP EMEA-001710-PIP02-14-M05 https://www.ema.europa.eu/en/documents/pip-decision/p/0325/2020-ema-decision-13-august-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2019. Peginterferon β PIP EMEA-001129-PIP01-11-M04 https://www.ema.europa.eu/en/documents/pip-decision/p/0371/2019-ema-decision-14-november-2019-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2018. Ponesimod PIP EMEA-000798-PIP01-09-M01 https://www.ema.europa.eu/en/documents/pip-decision/p/0128/2018-ema-decision-11-april-2018-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2017. Siponimod PIP EMEA-000716-PIP01-09-M02 https://www.ema.europa.eu/en/documents/pip-decision/p/0098/2017-ema-decision-11-april-2017-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2017. Teriflunamide PIP EMEA-001094-PIP01-10-M04. https://www.ema.europa.eu/en/documents/pip-decision/p/0165/2017-ema-decision-3-july-2017-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2013. Cebranopadol PIP EMEA-001305-PIP01-12 https://www.ema.europa.eu/en/documents/pip-decision/p/0145/2013-ema-decision-3-july-2013on-agreement-paediatric-investigation-plan-granting-deferral-granting_en.pdf
- EMA 2019. Fentanyl HCl PIP EMEA-001509-PIP01-13 https://www.ema.europa.eu/en/documents/pip-decision/p/0237/2019-ema-decision-16-july-2019-acceptance-modification-agreed-paediatric-investigation-plan-fentanyl_en.pdf
- EMA 2010. Fentanyl citrate PIP EMEA-000712-PIP01-09 https://www.ema.europa.eu/en/documents/pip-decision/p/231/2010-ema-decision-23-november-2010-agreement-paediatric-investigation-plan-granting-waiver-fentanyl_en.pdf
- EMA 2015 Gabapentin PIP EMEA-001310-PIP01-12-M02 https://www.ema.europa.eu/en/documents/pip-decision/p/0250/2015-ema-decision-30-october-2015-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2009. Glucose MH PIP EMEA-000221-PIP01-08 https://www.ema.europa.eu/en/documents/pip-decision/p/45/2009-european-medicines-agency-decision-24-march-2009-agreement-paediatric-investigation-plan_en.pdf
- EMA 2020. Methoxyflurane PIP EMEA-000334-PIP01-08-M09 https://www.ema.europa.eu/en/documents/pip-decision/p/0178/2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2012. Morphine HCl PIP EMEA-000711-PIP01-09 https://www.ema.europa.eu/en/documents/pip-decision/p/0001/2012-ema-decision-20-january-2012-agreement-paediatric-investigation-plan-granting-waiver-morphine_en.pdf
- EMA 2015. Naloxone PIP EMEA-001567-PIP01-13-M01 https://www.ema.europa.eu/en/documents/pip-decision/p/0219/2015-ema-decision-2-october-2015-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2008. Paracetamol PIP EMEA-000130-PIP01-07 https://www.ema.europa.eu/en/documents/pip-decision/p/96/2008-european-medicines-agency-decision-3-november-2008-application-agreement-paediatric/2006_en.pdf
- EMA 2011. Rizatriptan PIP EMEA-000084-PIP02-10 https://www.ema.europa.eu/en/documents/pip-decision/p/27/2011-ema-decision-28-january-2011on-agreement-paediatric-investigation-plan-granting-deferral_en.pdf
- EMA 2014. Tapentadol HCl EMEA-000325-PIP01-08-M03 https://www.ema.europa.eu/en/documents/pip-decision/p/0095/2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2016. Tapentadol HCl EMEA-000485-PIP01-08-M04 https://www.ema.europa.eu/en/documents/pip-decision/p/0043/2016-ema-decision-26-february-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2017. Tapentadol HCl PIP EMEA-000018-PIP01-07-M14 https://www.ema.europa.eu/en/documents/pip-decision/p/0355/2017-ema-decision-1-december-2017-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2014. Tapentadol HCl PIP EMEA-000486-PIP01-08-M03 https://www.ema.europa.eu/en/documents/pip-decision/p/0097/2014-ema-decision-7-april-2014-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2016 Tapentadol HCl PIP EMEA-000495-PIP01-08-M09 https://www.ema.europa.eu/en/documents/pip-decision/p/0091/2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2016. Tapentadol HCl PIP EMEA-000494-PIP01-08-M09 https://www.ema.europa.eu/en/documents/pip-decision/p/0092/2016-ema-decision-18-march-2016-acceptance-modification-agreed-paediatric-investigation-plan_en.pdf
- EMA 2011. Telcagepant PIP EMEA-000274-PIP01-08-M01 https://www.ema.europa.eu/en/documents/pip-decision/p/44/2011-ema-decision-3-march-2011-acceptance-modification-agreed-paediatric-investigation-plan/2006-eur_en.pdf
- Rose K, Grant-Kels JM. Pediatric melanoma – the whole (conflicts of interest) story. Int J Womens Dermatol. 2018,Nov 19;52:110–115. https://doi.org/10.1016/j.ijwd.2018.10.020.
- Rose K. Pediatric oncology at the crossroads: a call for change. Editorial Pharmaceut Med. 2020 Oct 7; https://rdcu.be/b8drm
- Geoerger B, Bergeron C, Gore L, et al. Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. Eur J Cancer. 2017;86:358–363.
- Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: a phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer. 2018 May;65(5): e26947. https://doi.org/10.1002/pbc.26947.
- Hwang TJ, Tomasi PA, Bourgeois FT. Delays in completion and results reporting of clinical trials under the paediatric regulation in the European Union: a cohort study. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002520
- Berg AT, Goldmann S. Getting serious about the early-life epilepsies: lessons from the world of pediatric oncology. Neurology. 2018 May 1;90(18):842–848. https://doi.org/10.1212/WNL.0000000000005423
- Vt D Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008 Nov 1;6821:8643–8653. https://doi.org/10.1158/0008-5472.CAN-07-6611.
- Adamson PC. Improving the outcome for children with cancer: development of targeted new agents. CA Cancer J Cli. 2015 May-Jun;65(3):212–220. DOI:https://doi.org/10.3322/caac.21273.
- Casanova M, Enis Özyar E, Patte C, et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5‑ fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol. 2016 Feb;77(2):289–298. DOI:https://doi.org/10.1007/s00280-015-2933-2.
- Petersson F. Nasopharyngeal carcinoma: a review. Semin Diagn Pathol. 2015 Jan;32(1):54–73.
- Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis. 2006 Jun 26;1:23. https://doi.org/10.1186/1750-1172-1-23.
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439–448. https://doi.org/10.1056/NEJMoa1709866
- FDA 2019. Considerations for the inclusion of adolescent patients in adult oncology clinical trials. Guidance for Industry. https://www.fda.gov/media/113499/download
- H.R.1231 - RACE for children act 115th congress (2017-2018). https://www.congress.gov/bill/115th-congress/house-bill/1231
- Reaman GH FDARA 2017 and the RACE for children act: implications for pediatric cancer drug development. Available online: https://www.accelerate-platform.eu/wp-content/uploads/sites/4/2018/02/1640-REAMAN.pdf
- Curesearch for children’s cancer. The RACE for children act: a game changer for children’s cancer. https://curesearch.org/The-RACE-for-Children-Act-A-Game-Changer-for-Childrens-Cancer
- Pearson ADJ, Karres D, Reaman G, et al. The RACE to accelerate drug development for children with cancer. Lancet Child Adolesc Health. 2020 Oct;4(10):714–716. DOI:https://doi.org/10.1016/S2352-4642(20)30247-9.
- Endorsements of RACE Act. The RACE for children act coalition. https://www.kidsvcancer.org/race-for-children-act/endorsements-for-race-act/
- Ten leading causes of death by age group, United States – 2018. https://www.cdc.gov/injury/images/lc-charts/leading_causes_of_death_by_age_group_2018_1100w850h.jpg
- Rose K, Neubauer D, Grant-Kels JM. Too many avoidable suicides occur worldwide in young patients. A Rev Rambam Maimonides Med J. 2019, Sep 18;10:e0026. https://doi.org/10.5041/RMMJ.10374.
- Hardin AP, Hackell JM. Committee on practice and ambulatory medicine. Age limit of pediatrics. Pediatrics. 2017;140(3):e20172151. https://pediatrics.aappublications.org/content/pediatrics/140/3/e20172151.full.pdf
- Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321–327. DOI:https://doi.org/10.1038/nature25480.
- Ma X, Liu Y, Liu Y, et al. Pan cancer genome and transcriptome analyses of 1699 paediatric leukaemias and solid tumours. Nature. 2018;555(7696):371–376. DOI:https://doi.org/10.1038/nature25795.
- Sweet-Cordero EA, Biegel JA. The genomic landscape of pediatric cancers: implications for diagnosis and treatment. Science. 2019;363(6432):1170–1175.
- Pearson AD, Herold R, Rousseau R, et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. Eur J Cancer. 2016;62:124–131.
- AAP 1995: guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations, committee on drugs. Am Acad Pediatr Pediatrics. 1995 Feb;952:286–294. https://pediatrics.aappublications.org/content/pediatrics/95/2/286.full.pdf
- Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007 Feb 7;297(5):480–488. https://doi.org/10.1001/jama.297.5.480.
- Plate V The impact of off-label, compassionate and unlicensed use on health care laws in preselected Countries. http://hss.ulb.uni-bonn.de/2009/1936/1936.pdf
- Adashi EY, Walters LB, Menikoff JA. The belmont report at 40: reckoning with time. Public Health. 2018 Oct;108(10):1345–1348.
- Rose CD. Ethical conduct of research in children: pediatricians and their IRB (Part 1 of 2). Pediatrics. 2017 May;139(5):66.
- McKay KA, Ernstsson O, Manouchehrinia A, et al. Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. J. Neurology. 2020 Mar 3;94(9):e932–e941. DOI:https://doi.org/10.1212/WNL.0000000000008667
- Chen Z, Brodie MJ, Kwan P. What has been the impact of new drug treatments on epilepsy? Curr Opin Neurol. 2020 Apr;33(2):185–190.
- Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus – report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015 Oct;56(10):1515–1523. DOI:https://doi.org/10.1111/epi.13121.
- Berg AT, Baca CB, Loddenkemper T, et al. Priorities in pediatric epilepsy research: improving children’s futures today. Neurology. 2013 Sep 24;8113:1166–1175. https://doi.org/10.1212/WNL.0b013e3182a55fb9.
- Momper JD, Mulugeta Y, Green DJ, et al. Adolescent dosing and labeling since the food and drug administration amendments act of 2007. JAMA Pediatr. 2013 Oct;167(10):926–932. DOI:https://doi.org/10.1001/jamapediatrics.2013.465.
- Paoletti X, Geoerger B, Doz F, et al. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’ trials. Eur J Cancer. 2013 Jul;49(10):2392–2402. DOI:https://doi.org/10.1016/j.ejca.2013.02.028.
- Laughon MM, Benjamin DK. Mechanisms to provide safe and effective drugs for children. Pediatrics. 2014 Aug;134(2):e562–3.
- Laughon MM, DK B Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol. 2011;4:643–652. DOI:https://doi.org/10.1586/ecp.11.43.
- Balevic SJ, Cohen-Wolkowiez M. Innovative study designs optimizing clinical pharmacology research in infants and children. J Clin Pharmacol. 2018 Oct;58(Suppl 10):S58–S72. DOI:https://doi.org/10.1002/jcph.1053.
- Sardella M, Belcher G. Pharmacovigilance of medicines for rare and ultrarare diseases. Ther Adv Drug Saf. 2018 Aug 14;911:631–638. https://doi.org/10.1177/2042098618792502.
- Ruperto N, Eichler I, Herold R, et al. A European network of paediatric research at the European Medicines Agency (Enpr-EMA). Arch Dis Child. 2012 Mar;97(3):185–188. DOI:https://doi.org/10.1136/archdischild-2011-300286.
- Enpr-EMA https://www.ema.europa.eu/en/partners-networks/networks/european-network-paediatric-research-european-medicines-agency-enpr-ema
- Enpr-EMA mission statement https://www.ema.europa.eu/en/documents/other/mission-statement-european-network-paediatric-research-european-medicines-agency-enpr-ema_en.pdf
- Enpr-EMA brochure https://www.ema.europa.eu/en/documents/leaflet/european-network-paediatric-research-european-medicines-agency_en.pdf
- Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House Publishers; 2004.
- Gotzsche PC. Deadly psychiatry and organised denial. artpeople publishers. København Denmark; 2015.
- Goldacre B. Bad pharma: how drug companies mislead doctors and harm patients. London UK: HarperCollinsPublishers; 2012.
- International Committee of Medical Journal Editors (ICMJE) Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. http://www.icmje.org/recommendations/
- Kuhn TS. The copernican revolution: planetary astronomy in the development of western thought. Cambridge MA: Harvard University Press; 1990.